InterMune (ITMN) Reports Smaller-Than-Expected Loss; Guides In-line

November 5, 2009 5:11 PM EST

InterMune Inc (NASDAQ: ITMN) reports a Q3 loss of $0.19, 2 cents better than the analyst estimate of ($0.21). Revenue for the quarter was $23.3 million, which compares to the estimate of $26.70 million.

Revenue: 2009 revenue, including Actimmune® and milestone payments from Roche, is expected to be in a range of approximately $45 to $50 million. Actimmune revenue represents approximately 50 percent of this revenue range. (Consensus is $48.02 million)


Related Categories

Earnings
Guidance

Stocks Mentioned

ITMN 15.60

+0.10 +0.65%
Volume: 850,326
Track ITMN


Add Your Comment





Follow StreetInsider.com On Twitter